Presentations

October 17, 2017 Investor Day Presentation

Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, hosted an Investor Day on Tuesday, October 17, 2017, from 12:00 p.m. to 3:00 p.m. ET at the Lotte Palace Hotel in New York City.

During the Investor Day, Paratek’s management team and experts in the field of antibiotics development and infectious disease will discuss progress of the clinical development program and pre-commercialization activities for omadacycline.

The meeting featured presentations by key opinion leaders including:

  • George Zhanel, Ph.D., University of Manitoba
  • George Sakoulas, M.D., University of California San Diego
  • Fredrick M. Abrahamian, DO, FACEP, FIDSA, David Geffen School of Medicine at UCLA

 

October 17, 2017 Investor Day Webcast

Paratek’s management team and experts in the field of antibiotics development and infectious disease discuss progress of the clinical development program and pre-commercialization activities for omadacycline.

 

September 15, 2017 Corporate Presentation

Paratek Pharmaceuticals corporate presentation deck

 

September 7, 2017 Baird’s 2017 Global Healthcare Conference 

Paratek Chief Commercial Officer Adam Woodrow presentation at RW Baird Investor Conference

 

July 17, 2017 OASIS-2 ABSSSI Trial Top-Line Results Investor Presentation

Top-line findings from the omadacycline OASIS-2 ABSSSI trial

  

November 17, 2016 R&D Day Presentation

During the R&D day, Paratek’s management team and opinion leaders in the field of antibiotics development and infectious disease discussed progress of the clinical development program for omadacycline, including the following:

  • Provided a company update
  • Discussed the company’s efforts to advance clinical development for omadacycline’s use in UTI
  • Reported results from additional registration enabling Phase 1 studies
  • Clinical unmet needs in ABSSSI, CABP and UTI and the value of an IV and Oral treatment option

 

4/5/16 Key Opinion Leader Breakfast on Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Slides from a keynote presentation by William O'Riordan, M.D., who discusses current therapeutic approaches to ABSSSIs. Members of the Paratek executive management team also provide an overview of the Company’s ongoing clinical development work with omadacycline, which is currently undergoing Phase 3 trials for the treatment of ABSSSIs and community acquired bacterial pneumonia (CABP).